GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (FRA:MWG0) » Definitions » Research & Development

InMed Pharmaceuticals (FRA:MWG0) Research & Development : €2.95 Mil (TTM As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is InMed Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. InMed Pharmaceuticals's Research & Development for the three months ended in Mar. 2024 was €0.60 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €2.95 Mil.

InMed Pharmaceuticals Research & Development Historical Data

The historical data trend for InMed Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals Research & Development Chart

InMed Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.80 5.16 4.43 6.89 3.45

InMed Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 0.58 1.21 0.56 0.60

InMed Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InMed Pharmaceuticals  (FRA:MWG0) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

InMed Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

InMed Pharmaceuticals (FRA:MWG0) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (FRA:MWG0) » Definitions » Research & Development
Comparable Companies
CWBR CNSP GMDAQ MBIO ARDS PXMD SCNI ELOX GLMD SLRX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
INM:USA MWG0:Germany
Address
815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4
Website
https://www.inmedpharma.com
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

InMed Pharmaceuticals (FRA:MWG0) Headlines

No Headlines